AnaptysBio, Inc. (ANAB) - What Are Analysts Saying About This Stock?

Key Points

• Analyst sentiment is broadly positive: AnaptysBio has a “Moderate Buy” consensus among 16 analysts, with 12 buy ratings, three holds and one sell. The average 12-month price target is $75.67.
• Some analysts have become more cautious: JPMorgan cut its price target to $60 while maintaining an overweight rating, and Scotiabank and Wall Street Zen moved to hold ratings.
• Quarterly results beat estimates: AnaptysBio reported earnings of $5.11 per share versus consensus expectations for a $0.46 loss, and revenue of $27.49 million versus estimates of $14.06 million.

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $75.67.

ANAB has been the topic of several research analyst reports. Wall Street Zen downgraded AnaptysBio from a "buy" rating to a "hold" rating in a research note on Sunday, October 4th. JPMorgan Chase & Co. decreased their price target on AnaptysBio from $70.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, September 30th. Cantor Fitzgerald reissued an "overweight" rating on shares of AnaptysBio in a report on Tuesday, September 22nd. TD Cowen dropped their price target on AnaptysBio from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, August 25th. Finally, Scotiabank downgraded shares of AnaptysBio to a "hold" rating and set a $70.00 price objective on the stock. in a report on Tuesday, August 25th.

AnaptysBio Stock Up 0.8%

ANAB opened at $48.77 on Thursday. The stock's fifty day moving average is $50.17 and its two-hundred day moving average is $56.31. The company has a market capitalization of $1.46 billion, a P/E ratio of 9.08 and a beta of 0.70. AnaptysBio has a 52 week low of $21.93 and a 52 week high of $72.36.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 EPS for the quarter, beating the consensus estimate of ($0.46) by $5.57. The firm had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%. During the same quarter last year, the firm posted ($1.30) earnings per share. Equities analysts anticipate that AnaptysBio will post -1.30 earnings per share for the current year.

Insider Activity

In other AnaptysBio news, Director Hollings Renton sold 5,000 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $49.87, for a total transaction of $249,350.00. Following the completion of the transaction, the director directly owned 10,995 shares of the company's stock, valued at approximately $548,320.65. This trade represents a 31.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 31.50% of the company's stock.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC increased its holdings in AnaptysBio by 55.2% in the third quarter. Voya Investment Management LLC now owns 17,488 shares of the biotechnology company's stock valued at $879,000 after buying an additional 6,223 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in shares of AnaptysBio during the third quarter worth approximately $474,000. Russell Investments Group Ltd. raised its stake in AnaptysBio by 420.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 84,859 shares of the biotechnology company's stock valued at $4,265,000 after purchasing an additional 68,558 shares during the last quarter. Penn Capital Management Company LLC purchased a new position in AnaptysBio in the 3rd quarter valued at $467,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in AnaptysBio in the 3rd quarter valued at $76,000.

About AnaptysBio

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company's pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.